EUVIMEDEUVIMED entdecken
Open Access

The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management

Sima Fansa iD, Andres Acosta

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Sima Fansa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Obesity Management. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past few decades, there has been a global surge in the prevalence of obesity, rendering it a globally recognized epidemic. Contrary to simply being a medical condition, obesity is an intricate disease with a multifactorial aetiology. Understanding the precise cause of obesity remains a challenge; nevertheless, there seems to be a complex interplay among biological, psychosocial and behavioural factors. Studies on the genetic factors of obesity have revealed several pathways in the brain that play a crucial role in food intake regulation. The best characterized pathway, thus far, is the leptin–melanocortin pathway, from which disruptions are responsible for the majority of monogenic obesity disorders. The effectiveness of conservative lifestyle interventions in addressing monogenic obesity has been limited. Therefore, it is crucial to complement the management strategy with pharmacological and surgical options. Emphasis has been placed on developing drugs aimed at replacing the absent signals, with the goal of restoring the pathway. In both monogenic and polygenic forms of obesity, outcomes differ across various interventions, likely due to the multifaceted nature of the disease. This underscores the need to explore alternative therapeutic strategies that can mitigate this heterogeneity. Precision medicine can be regarded as a powerful tool that can address this concern, as it values the understanding of the underlying abnormality triggering the disease and provides a tailored treatment accordingly. This would assist in optimizing outcomes of the current therapeutic approaches and even aid in the development of novel treatments capable of more effectively managing the global obesity epidemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Obesity ManagementHumansReceptor, Melanocortin, Type 4Precision MedicineObesityLeptinMelanocortins

Stichwörter der Autor:innen

antiobesity drugappetite controleffectivenessobesity therapy

Substanzen

Receptor, Melanocortin, Type 4LeptinMelanocortins

Autor:innen und Institutionen

  • Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Sima Fansa

Förderung

  • NIDDK NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Fansa, S., & Acosta, A. (2024). The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15555

Vancouver

Fansa S, Acosta A. The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15555

BibTeX
@article{Fansa2024,
  author = {Fansa, Sima and Acosta, Andres},
  title = {The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15555}
}
Kostenlos starten →